吸入糖皮质激素联合茶碱与联合长效β_2受体激动剂治疗哮喘的临床对照研究

The clinical control study of inhaled corticosteroid plus theophylline and combined with long-lasting β_2 agonists for asthma

目的探讨吸入糖皮质激素联合茶碱与联合长效β2受体激动剂治疗哮喘的效果。方法选取2013年10月-2014年12月我院呼吸科就诊的哮喘患者115例,随机分为观察组（ICS＋LABA）58例及对照组（ICS＋茶碱）57例。观察两组患者临床疗效,治疗前后肺功能变化及不良反应情况。结果观察组患者总有效率94.83%明显高于对照组84.21%（P〈0.05）。两组患者治疗后FEV1,FVC,VC,PEF等指标皆明显高于治疗前,观察组治疗后高于对照组（P〈0.05）。观察组不良反应发生率10.34%明显低于对照组28.06%（P〈0.05）。结论吸入糖皮质激素联合长效β2受体激动剂治疗哮喘临床疗效显著,不良反应少,值得临床推广。

Objective To explore the clinical control study of inhaled corticosteroid plus theophylline and combined with long-lasting β2 agonists for asthma. Methods 115 patients with asthma from October 2014 to December 2013 in our hospital were randomly divided into observation group（ICS＋LABA） 58 cases and control group（ICS＋theophylline） 57 cases. The clinical effect of the two groups of patients, the changes in the lung function and the adverse reactions of the two groups before and after the treatment were all observed and compared. Results The total effective of the observation group was 94.83%,significantly higher than the control group of 84.21%（P〈0.05）. The two groups of patients after treatment FEV1,FVC,VC,PEF and other indicators were significantly higher than before treatment, the observation group were higher than those in the control group after treatment（P〈0.05）.The incidence of adverse reactions in the observation group was 10.34%,which was significantly lower than that in the control group（28.06%）（P〈0.05）. Conclusion Inhaled corticosteroid combined with long-lasting β2 agonists for asthma clinical efficacy can significantly reduce adverse reactions, it is worthy of clinical application.